circRNA basic information
circBase ID: hsa_circ_0001805
Name: hsa_circ_CSPP1
Synonym: circRNA_0001805
Host Gene: hsa-miR-106a-5p, hsa-miR-320a
 
 
 
Disease basic information
DO ID:
 80208
DO name: non-alcoholic fatty liver disease
Disease details: nonalcoholic fatty liver disease
Species: human
Species details: human
Sample type: tissue, cell line, PDX
Sample type details: human Hepatocytes
circRNA-disease information
Detected method:
Q
Detected method confidence High
Expression pattern:
DN
Associated gene: ABCA1, CPT1
Associated microRNA: hsa-miR-106a-5p, hsa-miR-320a
Biological function: In vitro overexpression of circRNA_0001805 attenuated FFA-induced lipid metabolism disorder and hepatic inflammation and modulated the NF-¦ĘB pathway and CPT1/ABCA1 expression.In vivo circRNA_0001805 overexpression rescued HFD-induced lipid metabolism disorder and hepatic inflammation in an NAFLD mouse model.
Molecular mechanism: -
Survival: -
Supported No.:
 1
Description:

In summary, the present study revealed the protective role of circRNA_0001805 against NAFLD-induced fatty acid metabolism disorder and inflammation through the direct regulation of the miR-106a-5p/miR-320a/ABCA1/CPT1 axis. GA-RM/GZ/PL played a synergistic role against NAFLD-induced lipid metabolism disorder. By highlighting the potential value of circRNA_0001805 as a promising drug target for NAFLD treatment, our work provides deeper insight into ceRNA-mediated NAFLD pathogenesis and provides a new nanotherapy strategy for the treatment of NAFLD.
Other information
Title:

A nanodrug system overexpressed circRNA_0001805 alleviates nonalcoholic fatty liver disease via miR-106a-5p/miR-320a and ABCA1/CPT1 axis.

Journal: J Nanobiotechnology
Published: 2021/11/19
PubMed ID: 34789275